Emerging frontiers in immuno- and gene therapy for cancer

Background aims: The field of cell and gene therapy in oncology has moved rapidly since 2017 when the first cell and gene therapies, Kymriah followed by Yescarta, were approved by the Food and Drug Administration in the United States, followed by multiple other countries. Since those approvals, several new products have gone on to receive approval for additional indications. Meanwhile, efforts have been made to target different cancers, improve the logistics of delivery and reduce the cost associated with novel cell and gene therapies. Here, we highlight various cell and gene therapy-related technologies and advances that provide insight into how these new technologies will speed the translation of these therapies into the clinic. Conclusions: In this review, we provide a broad overview of the current state of cell and gene therapy-based approaches for cancer treatment -discussing various effector cell types and their sources, recent advances in both CAR and non-CAR genetic modifications, and highlighting a few promising approaches for increasing in vivo efficacy and persistence of therapeutic drug products.(c) 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Automated summary

The field of cell and gene therapy in oncology has seen rapid progress since the approval of the first therapies in 2017. Multiple new products have been approved for additional indications, and efforts have been made to target different cancers, improve delivery logistics, and reduce costs. This review provides an overview of the current state of cell and gene therapy-based approaches for cancer treatment, discussing various effector cell types, genetic modifications, and promising approaches for improving therapeutic efficacy and persistence.